Civitas Therapeutics secures $38m as it looks to advance a treatment for Parkinson’s disease Civitas Therapeutics Inc., a Chelsea-based biopharmaceutical company, announced the of a $38 million Series B financing. Civitas plans to use the proceeds for the late stage clinical development of its lead drug program, CVT-301, an inhaled formulation of levodopa (L-dopa) being developed for the rapid and reliable relief from debilitating motor fluctuations associated with Parkinson’s disease ...
Sept. 11, 2013 - Boston.com